What is Leerink Partnrs’ Forecast for LXEO FY2025 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at Leerink Partnrs reduced their FY2025 earnings estimates for shares of Lexeo Therapeutics in a research note issued to investors on Monday, March 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($3.18) for the year, down from their previous estimate of ($3.00). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($2.63) EPS.

A number of other research firms have also commented on LXEO. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Wednesday. Leerink Partners lowered their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Royal Bank of Canada cut their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Stock Up 3.0 %

Shares of NASDAQ LXEO opened at $4.11 on Thursday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market cap of $135.90 million, a P/E ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.50. The business has a 50-day simple moving average of $4.07 and a two-hundred day simple moving average of $6.63.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in Lexeo Therapeutics by 86.5% in the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after buying an additional 256,635 shares in the last quarter. State Street Corp grew its holdings in shares of Lexeo Therapeutics by 29.4% during the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after purchasing an additional 57,674 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new position in Lexeo Therapeutics in the 3rd quarter worth $11,307,000. Barclays PLC lifted its stake in Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after purchasing an additional 31,057 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in Lexeo Therapeutics by 18.9% during the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after buying an additional 599,203 shares during the period. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.